Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Int Immunopharmacol ; 81: 106249, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32066115

ABSTRACT

Renal interstitial fibrosis (RIF) often occurs in many chronic kidney diseases (CKD). Hirudin now is applied to treat fibrosis in some organs. In this study, we verified the treatment effects of hirudin on RIF in vivo and in vitro with the underlying mechanism. The RIF in vivo was the unilateral ureteral obstruction (UUO) model and RIF in vitro was the renal tubular epithelial cells induced by TGF-ß. The renal pathological changes and renal fibrosis were observed by hematoxylin and eosin (H&E) staining and Masson staining. The α-SMA in renal tissues was detected by immunohistochemistry. The inflammatory factors were analyzed by the ELISA assay. The cell apoptosis was observed by TUNEL assay. The related proteins of fibrosis, epithelial-mesenchymal transition (EMT) and apoptosis were assessed by western blot analysis. The experimental data demonstrated that hirudin decreased fibrosis, EMT, inflammation and cell apoptosis in renal tissues of UUO rats and TGF-ß-induced renal tubular epithelial cells. Furthermore, hirudin also reduced the expression of collgen-I, FN, α-SMA, N-cad, slug, E-cad, IL-1ß, IL-6 and TNF-α in mice serum and TGF-ß-induced renal tubular epithelial cells. The apoptosis related proteins (pro-caspase3, pro-caspase9, bcl2 and bax) expression was also down-regulated in renal tissues of UUO rats. In conclusion, hirudin depressed the fibrosis in renal tissues and renal tubular epithelial cells by inhibiting the inflammation, regulating the related proteins of fibrosis and ETM and decreasing the apoptosis of renal tubular epithelial cells. These findings may offer an effective treatment method for RIF.


Subject(s)
Anti-Inflammatory Agents/administration & dosage , Hirudin Therapy , Hirudins/administration & dosage , Inflammation/drug therapy , Kidney Tubules/pathology , Renal Insufficiency, Chronic/drug therapy , Ureteral Obstruction/drug therapy , Animals , Apoptosis , Cells, Cultured , Disease Models, Animal , Fibrosis , Humans , Male , Medicine, Chinese Traditional , Mice , Mice, Inbred BALB C , Rats
2.
Bioorg Med Chem ; 23(15): 4860-4865, 2015 Aug 01.
Article in English | MEDLINE | ID: mdl-26048027

ABSTRACT

3-Arylfuran-2(5H)-one derivatives show good antibacterial activity and were determined as tyrosyl-tRNA synthetase (TyrRS) inhibitors. In a systematic medicinal chemistry exploration, we demonstrated chemical opportunities to treat infections caused by Helicobacter pylori. Twenty 3-arylfuran-2(5H)-ones were synthesized and evaluated for anti-H. pylori, antioxidant and anti-urease activities which are closely interconnected with H. pylori infection. The results displayed that some of the compounds show excellent antioxidant activity, and good anti-H. pylori and urease inhibitory activities. Out of these compounds, 3-(3-methylphenyl)furan-2(5H)-one (b9) showed the most potent antioxidant activity (IC50=8.2 µM) and good anti-H. pylori activity (MIC50=2.6 µg/mL), and it can be used as a good candidate for discovering novel anti-gastric ulcer agent.


Subject(s)
Anti-Bacterial Agents/chemical synthesis , Anti-Ulcer Agents/chemical synthesis , Furans/chemistry , Anti-Bacterial Agents/metabolism , Anti-Bacterial Agents/pharmacology , Anti-Ulcer Agents/pharmacology , Anti-Ulcer Agents/therapeutic use , Antioxidants/chemistry , Binding Sites , Drug Evaluation, Preclinical , Furans/pharmacology , Furans/therapeutic use , Helicobacter pylori/drug effects , Helicobacter pylori/enzymology , Humans , Molecular Docking Simulation , Protein Structure, Tertiary , Stomach Ulcer/drug therapy , Tyrosine-tRNA Ligase/antagonists & inhibitors , Tyrosine-tRNA Ligase/metabolism , Urease/antagonists & inhibitors , Urease/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL